Meeting of the Advisory Committee on Blood and Tissue Safety and Availability, 40861 [2021-16120]

Download as PDF 40861 Federal Register / Vol. 86, No. 143 / Thursday, July 29, 2021 / Notices ANNUALIZED BURDEN HOUR TABLE Average burden per response Total burden hours Subpart B, § 46.207 ......................................................................................... Subpart C, § 46.306 (iii) and (iv) ...................................................................... Subpart D, § 46.407 ......................................................................................... 3 3 4 1 1 1 1 1 1 3 3 4 Total .......................................................................................................... ........................ ........................ ........................ 10 Sherrette A. Funn, Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary. [FR Doc. 2021–16159 Filed 7–28–21; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the Advisory Committee on Blood and Tissue Safety and Availability Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: The U.S. Department of Health and Human Services is hereby giving notice that the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) will hold a virtual meeting. The meeting will be open to the public. The committee will discuss recommendations to improve the supply chain and data infrastructure that supports the blood industry, especially during public health emergencies. To facilitate this discussion, key stakeholders from across the nation and around the world will present on hemovigilance, preparedness, inventory management systems and other relevant issues. DATES: The meeting will take place virtually on Tuesday, August 17, 2021 from approximately 10:00 a.m.–6:00 p.m. and Wednesday, August 18, 2021 from approximately 10:00 a.m.–6:00 p.m. Eastern Time (ET). Meeting times are tentative and subject to change. The confirmed times and agenda items for the meeting will be posted on the ACBTSA web page at https:// www.hhs.gov/oidp/advisory-committee/ blood-tissue-safety-availability/ meetings/2021-08-17/index.html when this information becomes available. FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, Department of Health and Human SUMMARY: VerDate Sep<11>2014 19:19 Jul 28, 2021 Jkt 253001 Services, Mary E. Switzer Building, 330 C Street SW, Suite L600, Washington, DC 20024. Email: ACBTSA@hhs.gov. ACBTSA is a discretionary Federal advisory committee. ACBTSA The Committee is governed by the provisions of the Federal Advisory Committee Act (FACA), Public Law 92–463, as amended (5 U.S.C. App), which sets forth standards for the formation and use of advisory committees. On the day of the meeting, please go to https:// www.hhs.gov/live/index.html to view the meeting. The public will have an opportunity to present their views to the ACBTSA orally during the meeting’s public comment session or by submitting a written public comment. Comments should be pertinent to the meeting discussion. Persons who wish to provide verbal or written public comment should review instructions at https://www.hhs.gov/oidp/advisorycommittee/blood-tissue-safetyavailability/meetings/2021-08-17/ index.html and respond by midnight August 9, 2021, ET. Verbal comments will be limited to three minutes each to accommodate as many speakers as possible. Written public comments will be accessible to the public on the ACBTSA web page prior to the meeting. ACBTSA functions to provide advice to the Secretary through the Assistant Secretary for Health on a range of policy issues to include: (1) Identification of public health issues through surveillance of blood and tissue safety issues with national survey and data tools; (2) identification of public health issues that affect availability of blood, blood products, and tissues; (3) broad public health, ethical, and legal issues related to the safety of blood, blood products, and tissues; (4) the impact of various economic factors (e.g., product cost and supply) on safety and availability of blood, blood products, and tissues; (5) risk communications related to blood transfusion and tissue transplantation; and (6) identification of infectious disease transmission issues for blood, organs, blood stem cells and tissues. The Committee has met SUPPLEMENTARY INFORMATION: BILLING CODE 4150–36–P jbell on DSKJLSW7X2PROD with NOTICES Number of responses per respondents Number of respondents 45 CFR part 46—HHS consultation process provision PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 regularly since its establishment in 1997. Dated: July 23, 2021. James J. Berger, Designated Federal Officer, Advisory Committee on Blood and Tissue Safety and Availability, Office of Infectious Disease and HIV/AIDS Policy. [FR Doc. 2021–16120 Filed 7–28–21; 8:45 am] BILLING CODE 4150–28–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Implementation Research to Improve Case Finding, Cascade Screening, and Treatment for Familial Hypercholesterolemia (FH). Date: September 2, 2021. Time: 10:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Bethesda, MD 20817 (Virtual Meeting). Contact Person: Susan Wohler Sunnarborg, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 208– Z, Bethesda, MD 20892, (301) 827–7987, susan.sunnarborg@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung E:\FR\FM\29JYN1.SGM 29JYN1

Agencies

[Federal Register Volume 86, Number 143 (Thursday, July 29, 2021)]
[Notices]
[Page 40861]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-16120]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the Advisory Committee on Blood and Tissue Safety and 
Availability

AGENCY: Office of the Assistant Secretary for Health, Office of the 
Secretary, Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The U.S. Department of Health and Human Services is hereby 
giving notice that the Advisory Committee on Blood and Tissue Safety 
and Availability (ACBTSA) will hold a virtual meeting. The meeting will 
be open to the public. The committee will discuss recommendations to 
improve the supply chain and data infrastructure that supports the 
blood industry, especially during public health emergencies. To 
facilitate this discussion, key stakeholders from across the nation and 
around the world will present on hemovigilance, preparedness, inventory 
management systems and other relevant issues.

DATES: The meeting will take place virtually on Tuesday, August 17, 
2021 from approximately 10:00 a.m.-6:00 p.m. and Wednesday, August 18, 
2021 from approximately 10:00 a.m.-6:00 p.m. Eastern Time (ET). Meeting 
times are tentative and subject to change. The confirmed times and 
agenda items for the meeting will be posted on the ACBTSA web page at 
https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2021-08-17/index.html when this information 
becomes available.

FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal 
Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS 
Policy, Office of the Assistant Secretary for Health, Department of 
Health and Human Services, Mary E. Switzer Building, 330 C Street SW, 
Suite L600, Washington, DC 20024. Email: [email protected].

SUPPLEMENTARY INFORMATION: ACBTSA is a discretionary Federal advisory 
committee. ACBTSA The Committee is governed by the provisions of the 
Federal Advisory Committee Act (FACA), Public Law 92-463, as amended (5 
U.S.C. App), which sets forth standards for the formation and use of 
advisory committees. On the day of the meeting, please go to https://www.hhs.gov/live/index.html to view the meeting. The public will have 
an opportunity to present their views to the ACBTSA orally during the 
meeting's public comment session or by submitting a written public 
comment. Comments should be pertinent to the meeting discussion. 
Persons who wish to provide verbal or written public comment should 
review instructions at https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2021-08-17/index.html and 
respond by midnight August 9, 2021, ET. Verbal comments will be limited 
to three minutes each to accommodate as many speakers as possible. 
Written public comments will be accessible to the public on the ACBTSA 
web page prior to the meeting.
    ACBTSA functions to provide advice to the Secretary through the 
Assistant Secretary for Health on a range of policy issues to include: 
(1) Identification of public health issues through surveillance of 
blood and tissue safety issues with national survey and data tools; (2) 
identification of public health issues that affect availability of 
blood, blood products, and tissues; (3) broad public health, ethical, 
and legal issues related to the safety of blood, blood products, and 
tissues; (4) the impact of various economic factors (e.g., product cost 
and supply) on safety and availability of blood, blood products, and 
tissues; (5) risk communications related to blood transfusion and 
tissue transplantation; and (6) identification of infectious disease 
transmission issues for blood, organs, blood stem cells and tissues. 
The Committee has met regularly since its establishment in 1997.

    Dated: July 23, 2021.
James J. Berger,
Designated Federal Officer, Advisory Committee on Blood and Tissue 
Safety and Availability, Office of Infectious Disease and HIV/AIDS 
Policy.
[FR Doc. 2021-16120 Filed 7-28-21; 8:45 am]
BILLING CODE 4150-28-P